



24 April 2019

(19-2694)

Page: 1/1

Original: English

**TURKEY – CERTAIN MEASURES CONCERNING THE PRODUCTION,  
IMPORTATION AND MARKETING OF PHARMACEUTICAL PRODUCTS**

**REQUEST TO JOIN CONSULTATIONS**

*Communication from the United States*

The following communication, dated 18 April 2019, from the delegation of the United States to the delegation of Turkey, and the delegation of the European Union, is circulated to the Dispute Settlement Body in accordance with Article 4.11 of the DSU.

---

This concerns the request for consultations by the European Union on *Turkey – Certain Measures Concerning the Production, Importation and Marketing of Pharmaceutical Products*, circulated on 10 April 2019 (WT/DS583/1). My authorities have instructed me to notify the consulting Members and the Dispute Settlement Body of the desire of the United States to be joined in these consultations, pursuant to Article 4.11 of the *Understanding on Rules and Procedures Governing the Settlement of Disputes*.

The United States has a substantial trade interest in these consultations. They concern certain measures of Turkey related to the production, importation, and marketing of pharmaceutical products. According to the consultations request, these measures include a "localisation requirement", a "technology transfer requirement", an "import ban on localised products", and a "prioritization measure", each alleged to be inconsistent with Turkey's obligations under the covered agreements. The United States is one of the world's leaders in the development, production, licensing, and marketing of pharmaceuticals, and, in 2018, the United States exported \$219 million of pharmaceutical products to Turkey.

---